Syncona Limited

Syncona Limited
BACIT Investments LP
Closed Ended Investment Company
Sector Specialist: Biotechnology & Healthcare
1.55 %
3 Year Sharpe
0 %
Fund Size
£ 1.8 billion
Discount Premium
The Company's investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Holding %
Blue Earth Diagnostics 17.45 %
Nightstar Therapeutics Plc 11.62 %
Autolus 7.95 %
Companies Of Less Than 1% Of Nav 4.79 %
The SFP Value Realization Fund Ltd USD 3.52 %
Polar UK Absolute Equity I Euro 3.44 %
Freeline Therapeutics 3.36 %
Funds Of Less Than 1% Of Nav 3.08 %
Maga Smaller Companies Ucits 2.96 %
Polygon European Equity Opportunity Fund 2.95 %
Region %
United Kingdom 51.79 %
Japan 40.68 %
Sector %
Financial Services 18.92 %
Consumer Cyclical 17.02 %
Industrials 15.00 %
Energy 11.77 %
Consumer Defensive 9.51 %
Basic materials 8.30 %
Communication Services 5.42 %
BACIT Investments LP
GY1 2JA, St. Peter Port, Guernsey
Legal Structure
Closed Ended Investment Company


Tom Henderson
Joined 10/26/2012
Arabella Cecil
Joined 10/26/2012
John McDonald
Joined 10/26/2012

McDonald has been a vice president and associate portfolio manager with Phoenix Investment Counsel since 1992. He joined the company in 1990 as a marketing coordinator for investment communications, and became a research analyst in 1991. McDonald began his career in 1989 as a financial services advisor for The America Group. McDonald earned his Chartered Financial Analyst designation in 1994. He was born November 29, 1967 in Waterbury, Connecticut.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.